Cipla Limited (CIPLA.BO)
INR 1525.7
(-1.55%)
INR 1525.7
(-1.55%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -3.15 Billion INR | -268.51% |
| 2022 | 1.87 Billion INR | -50.46% |
| 2021 | 3.78 Billion INR | -69.04% |
| 2020 | 12.21 Billion INR | -47.97% |
| 2019 | 23.46 Billion INR | -38.37% |
| 2018 | 38.07 Billion INR | 17.36% |
| 2017 | 32.44 Billion INR | -7.36% |
| 2016 | 35.02 Billion INR | -19.53% |
| 2015 | 43.52 Billion INR | 260.69% |
| 2014 | 12.06 Billion INR | 7.06% |
| 2013 | 11.26 Billion INR | 28.94% |
| 2012 | 8.74 Billion INR | 3941.85% |
| 2011 | -227.5 Million INR | -104.97% |
| 2010 | 4.57 Billion INR | 903.3% |
| 2009 | -569.9 Million INR | -105.42% |
| 2008 | 10.51 Billion INR | 89.1% |
| 2007 | 5.55 Billion INR | 6473.97% |
| 2006 | -87.2 Million INR | -102.05% |
| 2005 | 4.24 Billion INR | 85.79% |
| 2004 | 2.28 Billion INR | -3.74% |
| 2003 | 2.37 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -6.35 Billion INR | -104.22% |
| 2024 Q1 | 79.7 Billion INR | 2625.97% |
| 2023 Q2 | 1.61 Billion INR | -97.5% |
| 2023 Q4 | -3.15 Billion INR | -106.45% |
| 2023 FY | -3.15 Billion INR | -268.51% |
| 2023 Q3 | 48.9 Billion INR | 2936.75% |
| 2023 Q1 | 64.51 Billion INR | 3345.12% |
| 2022 Q3 | 41.85 Billion INR | 998.82% |
| 2022 Q4 | 1.87 Billion INR | -95.53% |
| 2022 FY | 1.87 Billion INR | -50.46% |
| 2022 Q1 | 41.23 Billion INR | 990.74% |
| 2022 Q2 | 3.8 Billion INR | -90.76% |
| 2021 Q1 | 37.5 Billion INR | 207.1% |
| 2021 FY | 3.78 Billion INR | -69.04% |
| 2021 Q4 | 3.78 Billion INR | -89.41% |
| 2021 Q3 | 35.68 Billion INR | 334.25% |
| 2021 Q2 | 8.21 Billion INR | -78.09% |
| 2020 Q1 | 20.08 Billion INR | -14.4% |
| 2020 Q4 | 12.21 Billion INR | -66.41% |
| 2020 Q3 | 36.34 Billion INR | 43.58% |
| 2020 FY | 12.21 Billion INR | -47.97% |
| 2020 Q2 | 25.31 Billion INR | 26.02% |
| 2019 Q3 | 22.27 Billion INR | -23.66% |
| 2019 Q4 | 23.46 Billion INR | 5.36% |
| 2019 Q1 | 27.34 Billion INR | -28.18% |
| 2019 FY | 23.46 Billion INR | -38.37% |
| 2019 Q2 | 29.17 Billion INR | 6.68% |
| 2018 Q2 | 37.54 Billion INR | 82.43% |
| 2018 FY | 38.07 Billion INR | 17.36% |
| 2018 Q4 | 38.07 Billion INR | 55.05% |
| 2018 Q3 | 24.55 Billion INR | -34.58% |
| 2018 Q1 | 20.57 Billion INR | -36.58% |
| 2017 Q1 | 15.27 Billion INR | -56.38% |
| 2017 Q3 | 23.68 Billion INR | -40.72% |
| 2017 Q2 | 39.95 Billion INR | 161.54% |
| 2017 Q4 | 32.44 Billion INR | 37.0% |
| 2017 FY | 32.44 Billion INR | -7.36% |
| 2016 FY | 35.02 Billion INR | -19.53% |
| 2016 Q3 | 15.82 Billion INR | -58.91% |
| 2016 Q1 | 14.51 Billion INR | -66.64% |
| 2016 Q4 | 35.02 Billion INR | 121.25% |
| 2016 Q2 | 38.52 Billion INR | 165.34% |
| 2015 Q3 | 6.51 Billion INR | -45.49% |
| 2015 FY | 43.52 Billion INR | 260.69% |
| 2015 Q1 | 9.54 Billion INR | -20.91% |
| 2015 Q2 | 11.94 Billion INR | 25.18% |
| 2015 Q4 | 43.52 Billion INR | 568.34% |
| 2014 Q3 | 16.57 Billion INR | -3.17% |
| 2014 Q2 | 17.12 Billion INR | 251.84% |
| 2014 FY | 12.06 Billion INR | 7.06% |
| 2014 Q1 | 4.86 Billion INR | -56.82% |
| 2014 Q4 | 12.06 Billion INR | -27.22% |
| 2013 Q2 | 10.69 Billion INR | -52.66% |
| 2013 FY | 11.26 Billion INR | 28.94% |
| 2013 Q4 | 11.26 Billion INR | 141.3% |
| 2013 Q3 | 4.67 Billion INR | -56.34% |
| 2013 Q1 | 22.59 Billion INR | 158.55% |
| 2012 Q4 | 8.74 Billion INR | 0.0% |
| 2012 FY | 8.74 Billion INR | 3941.85% |
| 2011 FY | -227.5 Million INR | -104.97% |
| 2010 FY | 4.57 Billion INR | 903.3% |
| 2009 FY | -569.9 Million INR | -105.42% |
| 2008 FY | 10.51 Billion INR | 89.1% |
| 2007 FY | 5.55 Billion INR | 6473.97% |
| 2006 FY | -87.2 Million INR | -102.05% |
| 2005 FY | 4.24 Billion INR | 85.79% |
| 2004 FY | 2.28 Billion INR | -3.74% |
| 2003 FY | 2.37 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Abbott India Limited | -20.51 Billion INR | 84.616% |
| Gland Pharma Limited | -14.67 Billion INR | 78.493% |
| GlaxoSmithKline Pharmaceuticals Limited | -674.11 Million INR | -368.114% |
| Kopran Limited | 850.3 Million INR | 471.115% |
| Marksans Pharma Limited | -4.29 Billion INR | 26.531% |
| NGL Fine-Chem Limited | 307.22 Million INR | 1127.133% |
| Pfizer Limited | -19.52 Billion INR | 83.835% |
| Sanofi India Limited | -3.87 Billion INR | 18.565% |
| SMS Pharmaceuticals Limited | 2.44 Billion INR | 229.028% |